Openai/694257a5-9a50-8004-b15d-8af3ca7857db
This conversation was exported from ChatGPT[1]
gpt-5-2-pro[edit | edit source]
User: 原始郵件[edit | edit source]
原始郵件 郵件 ID <[email protected]> 建立時間： 2025年12月17日清晨7:21 (傳輸時間：2 秒) 寄件者： JAMA <[email protected]> 收件者： friend <[email protected]> 主旨： New issue: Update to SOFA Score in Critically Ill Patients (SOFA-2), AI vs Human Coaching for Diabetes Prevention, Cutaneous Melanoma Review SPF： PASS，IP 74.214.206.14 瞭解詳情 DKIM： 'PASS'，網域 email.jamanetwork.com。瞭解詳情 DMARC： 'PASS'。瞭解詳情
下載原始郵件 複製到剪貼簿 Delivered-To: [email protected] Received: by 2002:a05:7000:dd4f:b0:7b5:6e26:e0d3 with SMTP id lb15csp862660mab;
Tue, 16 Dec 2025 15:21:07 -0800 (PST)
X-Google-Smtp-Source: AGHT+IEAI4nmNByPkRRTRz8xNTA4Xt63WP8atGZ3Wa8OL+PXoZ/ly9yWQac/Fe5cF521uqbh2xA+ X-Received: by 2002:a05:620a:1927:b0:8b2:ed01:b65b with SMTP id af79cd13be357-8bb3a383aeemr2018942585a.83.1765927267588;
Tue, 16 Dec 2025 15:21:07 -0800 (PST)
ARC-Seal: i=1; a=rsa-sha256; t=1765927267; cv=none;
d=google.com; s=arc-20240605;
b=MLhuGFdtB84c3FJI6nPE30Tc4eL+GRksDbe8a56PvV7bBIZMNz7UnnIEnx5aJSYBLc
tARsOVC7smR0f8d2YyYUSZs6OqN6voq3oi8rYhPVFOh+F5+g8lOJrOqSyc5i0DnvaNes
0kLcPVvBiB411PkyMQ1EvUPol2pSwWf34mOyAV/Bq+nM42P4ALouGSsKobrL7G2bTwlo
pZWxrK/bZmhFjAxz2w9E6YurNRKoGSLWLLuwxqq9rY1TRv29xYrgzQcthp2UC+igyMnh
4wRAwDcpCWC+z2Gd5iQhojum60regz+/mfYLpQSmCDsMltg+L0caiTeA0yyE0LWbiMNi
R2GA==
ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605;
h=list-unsubscribe-post:list-unsubscribe:content-transfer-encoding
:mime-version:subject:message-id:to:reply-to:from:date
:dkim-signature:dkim-signature;
bh=lRbjhPaWWcqbqU9N+oPTIcQ4mD7n89lSSiAhbGE60Ds=;
fh=T+1cAzDwU59AOoRV42gQlbZgZr40o0M3jf3McMmQlzQ=;
b=EjKGnkBh/1fxg36ZmyDe1WY2bOThm71OPSue5naSGljpa/bg50qSHeVlKCRrqlWZX6
eTvjfsVl8t32gLLNiy/W1baFS9YIx3NVWclbLXJa0YtSl2Pe+l0Rt131ScbDU+RLjOid
l7KxS64tzubRnqL1V/1EvK+OgAVCOEWayKCey2P4inENZ4CDM9dJ2kFs+ruI8v02HuYL
ia6LjIuRZ2/YmReKM6Sqnh2a6oWZWUB0haHuXvZ6weciyTZHV5aGTWSIWNgdNlqfiLbK
rZl+a15ea1q4u9i+n5D7hYCiID3kUq6Zermh6G5CW4MBm81bcT5si0v5maqSMRXl01zx
N9Rg==;
dara=google.com
ARC-Authentication-Results: i=1; mx.google.com;
dkim=pass [email protected] header.s=class header.b=aSuqXIze; dkim=pass [email protected] header.s=class header.b=JraMh09O; spf=pass (google.com: domain of [email protected] designates 74.214.206.14 as permitted sender) smtp.mailfrom=bounce-ndptqwpjtnrkkrnqrpdkytqdknkhyrmjjj@email.jamanetwork.com; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=email.jamanetwork.com
Return-Path: <[email protected]> Received: from mail1.email.jamanetwork.com (mail1.email.jamanetwork.com. [74.214.206.14])
by mx.google.com with ESMTPS id af79cd13be357-8be56f768c3si343270585a.525.2025.12.16.15.21.07
for <[email protected]>
(version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256);
Tue, 16 Dec 2025 15:21:07 -0800 (PST)
Received-SPF: pass (google.com: domain of [email protected] designates 74.214.206.14 as permitted sender) client-ip=74.214.206.14; Authentication-Results: mx.google.com;
dkim=pass [email protected] header.s=class header.b=aSuqXIze; dkim=pass [email protected] header.s=class header.b=JraMh09O; spf=pass (google.com: domain of [email protected] designates 74.214.206.14 as permitted sender) smtp.mailfrom=bounce-ndptqwpjtnrkkrnqrpdkytqdknkhyrmjjj@email.jamanetwork.com; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=email.jamanetwork.com
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; s=class; d=email.jamanetwork.com; h=Date:From:Reply-To:To:Message-ID:Subject:MIME-Version:Content-Type: Content-Transfer-Encoding:List-Unsubscribe:List-Unsubscribe-Post; [email protected]; bh=lRbjhPaWWcqbqU9N+oPTIcQ4mD7n89lSSiAhbGE60Ds=; b=aSuqXIzegtgQq+XiQE06hGvmiuHGZJyx1njbU6gsyW+lR07SdJDgukzUDYHRW7Ql9ZIT0UX98hvN
EQpxMJVd9g72iZ8EgBhPoCIFYA/sKyzBr5gtaF2TRmoS4q6uVRlaOnUH0JPIu9pBq62W1lkIKWjT vH60a6sw52AiXZI+3Ac=
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; s=class; d=email.jamanetwork.com; h=Date:From:Reply-To:To:Message-ID:Subject:MIME-Version:Content-Type: Content-Transfer-Encoding:List-Unsubscribe:List-Unsubscribe-Post; bh=lRbjhPaWWcqbqU9N+oPTIcQ4mD7n89lSSiAhbGE60Ds=; b=JraMh09Okr1ULLFRLdAQYPNM0uiF8XdUMOf6JkIoy/Kqb3J8da+bgmfNaeIBmwjztuJiKICA2Iz8
Z4pNzgqHaJamxSiNf8IMckhq00dM4MeO8VDovLBBb2cSAa+sYmZI3sonT6/Jnfv8btpedzUn6EzU cfzDUAVE8MMRZvdTfxQ=
Received: by mail1.email.jamanetwork.com id h87km6398q8a for <[email protected]>; Tue, 16 Dec 2025 17:21:05 -0600 (envelope-from <[email protected]>) Date: Tue, 16 Dec 2025 17:21:05 -0600 (CST) From: JAMA <[email protected]> Reply-To: JAMA Replies <[email protected]> To: friend <[email protected]> Message-ID: <[email protected]> Subject: New issue: Update to SOFA Score in Critically Ill Patients (SOFA-2), AI vs Human Coaching for Diabetes Prevention, Cutaneous Melanoma Review MIME-Version: 1.0 Content-Type: text/html; charset=UTF-8 Content-Transfer-Encoding: quoted-printable X-AMA: cpjmjdhhpcdjftdtfjpmpqqccl mrdjzqqqcrmkgmtvvczcvmprkjvclnzkfgthlqgfjmmjftjlcmdgtcm tjttpmdhqp List-Unsubscribe: <mailto:unsub-410684-7997-9D27C8885D9A491BB5C5B93DA7B56FCA@email.jamanetwork.com>,<https://click1.email.jamanetwork.com/Unsub.do?pup=hnhsvnwmszhffhzfrqhpmmmcrflsfvjjcpcjfbrlhjcwgplzc&List-Unsubscribe=One-Click> List-Unsubscribe-Post: List-Unsubscribe=One-Click
<head style=3D"box-sizing: border-box">
<meta content=3D"width=3Ddevice-width" name=3D"viewport" style=3D"box-siz=
ing: border-box"/>
<style style=3D"box-sizing: border-box" type=3D"text/css">
.cmeLink a:hover { text-decoration: underline !important; } .cmeLink a {=
color: #981B1E !important; text-decoration: none; } .cmelink { border-left=
- 2px solid #981B1E !important; font-size:14px !important; font-weight:bold =
!important; padding-left:6px !important; color: #981B1E !important; }
.addressText {color: #333; font-family: Helvetica, Arial, sans-=
serif; font-size: 10px; line-height: 1.25;margin:0;text-align: left;}
.alertDate {padding: 14px 0 10px 20px;font-family: Helvetica, A=
rial, sans-serif; font-size: 11px; font-style: normal; font-weight: bold; l= etter-spacing: 0.5px;text-align: left; color: #981B1E !important; text-tran= sform: uppercase;}
.alertType {display: block; font-family: Helvetica, Arial, sans=
-serif; font-size: 24px; font-style: normal; font-weight: bold; letter-spac= ing: -1px; margin: 0px; padding: 0px; text-align: left; color: #222222 !imp= ortant;}
.articleContent {margin: 10px 0 24px 0;}
.articleContent ul {list-style-type: none;}
.articleContent:last-of-type {margin-bottom: 50px;}
.articleContent div {font-size: 12px; margin-top:6px;}
.articleLink {color: #000;font-weight: bold;text-decoration: no=
ne;}
.articleLink:hover {color: #981B1E !important;}
.articleType {border-top:1px solid #981B1E;color:#d71635;font-s=
ize:12px;font-weight:bold;letter-spacing:1px;padding:8px 0 0 0 ;margin: 35p= x 0 0 0;text-transform: uppercase;}
.articleType:first-of-type {margin:0;border-top:0;padding:0;}
.bodyText {color: #000; font-family: Helvetica, Arial, sans-ser=
if; font-size: 15px; line-height: 1.5;padding-right:30px;}
.disclaimer {border-bottom: 1px solid #ccc; margin-top:10px;pad=
ding: 0 20px 10px 23px;}
.featuredContent {border-top:0;color:#d71635;font-size:12px;fon=
t-weight:bold;letter-spacing:1px;padding:0 ;margin: 0 0 16px 0;text-transfo= rm: uppercase;}
.footerCopyright {color: #333; font-family: Helvetica, Arial, s=
ans-serif; font-size: 11px; line-height: 125%;margin:0;text-align: left;}
.footerText {color: #333; font-family: Helvetica, Arial, sans-s=
erif; font-size: 10px; margin-top:5px;text-align: left;}
.lockupContent {border-bottom:1px solid #981B1E; border-top:1px=
solid #981B1E; padding:15px 0;}
.preHeader {display: none !important;}
.readOnline {color: #555; font-family: Helvetica,Arial,sans-ser=
if;font-size: 10.5px; line-height: 1em;margin: 0 !important;padding: 0 !imp= ortant;}
.readOnline a {color: #0067dd;text-decoration:none;}
.redesignContainer {padding:0;}
.relatedArticleType { background-color: #fff; padding: 10px 0 5=
px 15px; line-height: 1.5em; font-size: 12px; }
.relatedArticleTypeName { font-weight: bold; margin-bottom: 0; =
padding-bottom: 0; }
.relatedArticleType ul { list-style-position: inside; padding-l=
eft:0; padding-top: 2px; margin-top: 0; margin-bottom: 0; padding-bottom: 0=
- line-height
- 1.5em; }
.relatedArticleType li { padding-bottom: 5px; }
.relatedArticleName { font-size: 12px !important; line-height: =
1.5em; }
.relatedArticleName a { font-size: 12px !important; line-height=
- 1.5em; }
.rightColumnText {color: #333; font-family: Helvetica,Arial,san=
s-serif;font-size: 12px; line-height: 1.5em;margin: 0 !important;padding: 0=
!important;}
.rightColumnLink:hover {color:#981B1E !important;}
.signatureContent {border-bottom:1px solid #981B1E; border-top:=
1px solid #981B1E; margin-bottom:10px; margin-top:15px;padding:15px 0;}
#socialIcons {vertical-align: middle; padding-top: 7px;}
.superClassification {font-weight:bold;}
.unsubText {color: #333; font-family: Helvetica, Arial, sans-se=
rif; font-size: 10px; line-height: 1.85;margin:10px 0 0 0;text-align: left;= }
@media only screen and (max-width: 480px) {
.alertDate {padding: 13px 0 12px 20px !important; font-size: 10=
px !important;}
.alertType {font-size: 16px !important;}
.articleContent div {font-size: 12px;}
.articleLink {font-size:17px !important;}
.footerText {font-size: 11px;}
.journalNameCell {padding-top:15px !important;}
.onlineFirstOptional {font-size:13px;}
.promoImage {display: none !important;width: 100%!important;}
.redesignContainer {padding:0 !important;}
.lockupPadding {padding-bottom:35px !important;}
body, table, td, p, a, li, blockquote {-webkit-text-size-adjust=
- none !important;}
table[id=3D"templateContainer"] {width:100% !important;max-widt=
h:600px !important;}
table[class=3D"bannerTable"] {max-width:600px !important;width:=
100% !important;}
table[id=3D"bodyTable"] {width:100%!important;max-width:600px!i=
mportant;}
table[class=3D"alertContentTable"] {width:100%!important;max-wi=
dth:420px!important;}
table[class=3D"rightColumn"] {width:100%!important;max-width:42=
0px!important;}
img[class=3D"rightColumnImage"] {width: 100%!important;}
img[class=3D"journalName"] {height: 32px !important;width:auto=
- }
td[id=3D"socialIcons"] {display: none !important;}
td[class=3D"bodyText"] {padding-right:0 !important;}
p[class=3D"rightColumnText"] {font-size: 14px !important;}
th[class=3D"sectionContainer"] {display: block !important;heigh=
t:auto !important;max-width: 600px !important;padding-left: 0;width: 100% != important;}
}
* {box-sizing: border-box;}
.articleContent.with-image {background: #f3f3f3;border: 1px sol=
id #ccc;padding: 15px;width: 100%;}
.articleContent.with-image .relatedArticleType {background-colo=
r: #f3f3f3 !important;}
a.image-link img {width:100%;max-width:100%;padding-bottom: 9px=
!important;}
img.article-image {width: 100%;max-width: 100%;padding-bottom: =
9px !important;}
</style>
<style style=3D"box-sizing: border-box" type=3D"text/css">
.c1-ui-state-hover {background-color:yellow !important; padding:5px !imp=
ortant }
</style> </head>
<body style=3D"box-sizing: border-box">
<img src=3D"https://d7f2e3.www.efeedbacktrk.com/qpmdqwpr=
hhhtgqdjtvdmytygrgtydsqjpygfbrjmdsnhf_blfjpdqbjypcqgzljpgz.gif" width=3D"0"=
height=3D"0" alt=3D"">
Read the latest research from JAMA, which provides readers throughout th=
e world with essential medical information and a unique forum for discussio= ns shaping the future of medical practice and public health.
<tbody style=3D"box-sizing: border-box"> </tbody>
|
Trouble viewing this email? <a href=3D"https://click1.email.jamanetwork.com/ViewMessage.do?m=3D= xgpjccj&r=3Drnckcjvwk&s=3Dezpqlszwpppblqvtqrjjbwbjqylvzjbhkwv&q=3D176592415= 9&a=3Dview" id=3D"auto_assign_link_num_236" name=3D" Campaign ViewOnlineURL= " style=3D"box-sizing: border-box;color: #0067dd;text-decoration: none"> Read it Online </a> |
|||||||||||||||||||||||||
<tbody style=3D"box-sizing: border-box">
</tbody>
|
<a href=3D'https://click1.email.jamanetwork=
.com/t.do?id=3D193165:410684:9D27C888-5D9A-491B-B5C5-B93DA7B56FCA:176592415= 9&a=3D9D27C888-5D9A-491B-B5C5-B93DA7B56FCA&b=3Drnckcjvwk'>Link</a> <= /body> </html>
Assistant: 來源資訊[edit | edit source]
來源資訊[edit | edit source]
- 來源：JAMA（JAMA Network）
- 日期：2025-12-16（Volume 334, Number 23）
- 主題：New issue: Update to SOFA Score in Critically Ill Patients (SOFA-2), AI vs Human Coaching for Diabetes Prevention, Cutaneous Melanoma Review
本期快選（最多 5 篇）[edit | edit source]
- Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score[2]-2%20Score)｜類型：Original study｜一句導讀：330 萬 ICU 建模驗證，AUROC 0.79 優於 SOFA 0.77，重症分層可更新。 JAMA Network[3]
- An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial[4]｜類型：Original study｜一句導讀：724 人 RCT，AI 介入複合達標不劣於人類教練（差 1.0%，95%CI −6.1～8.1）。 JAMA Network[5]
- Arsenic Exposure Reduction and Chronic Disease Mortality[6]｜類型：Original study｜一句導讀：尿砷每 IQR 下降 197 μg/g，慢性病死亡 aHR 0.78；高→低於中位數 aHR 0.46。 PubMed[7]
- Cutaneous Melanoma: A Review[8]｜類型：Review｜一句導讀：黑色素瘤 95% 為皮膚型；全球年約 30 萬新案，早期手術、進展期免疫/標靶重點整理。 JAMA Network[9]
- Recurrent Clostridioides difficile Infections[10]｜類型：JAMA Insights｜一句導讀：復發 CDI 的診斷、治療與再發預防流程化整理，臨床可直接套用。 JAMA Network[11]
全部條目導讀（依輸入出現順序）[edit | edit source]
This Week in JAMA[edit | edit source]
- Audio Highlights: November 21, 2025[12] 中文標題：音訊精華（2025/11/21） 類型：Audio（This Week in JAMA） 導讀：用短音訊快速掃描本期重點（含肺癌篩檢、周邊神經病變回顧、砷暴露與死亡等），適合作為「先聽再挑文」的入口。 JAMA Network[13]
Original Investigation[edit | edit source]
- An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial[14] 中文標題：糖尿病預防計畫：AI 生活型態介入 vs 人類教練的隨機試驗 類型：Original study（RCT；AI in Medicine） 導讀：RCT（n=724，前期糖尿病）：AI vs 人類教練。12 月複合達標 42.4% vs 41.4%，差 1.0%（95%CI −6.1～8.1）達非劣；活動量未非劣。 JAMA Network[15]
- Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score[16]-2%20Score) 中文標題：SOFA-2 器官衰竭評分的開發與驗證 類型：Original study（預後/風險評分開發與驗證；Caring for the Critically Ill Patient） 導讀：330 萬成人 ICU 聯邦分析建模驗證；SOFA-2（0–24，納用藥/器官支持）院內死亡 AUROC 0.79 優於 SOFA 0.77，利於重症分層更新；GI/免疫未納入。 JAMA Network[17]
- Arsenic Exposure Reduction and Chronic Disease Mortality[18] 中文標題：砷暴露下降與慢性病死亡率 類型：Original study（前瞻性隊列；環境健康） 導讀：前瞻隊列（10,977 人）追蹤至 2022：尿砷每 IQR↓197 μg/g，慢性病死亡 aHR 0.78；高→低於中位數 aHR 0.46，支持砷緩解與死亡下降相關。 PubMed[19]
Research Letter[edit | edit source]
- Tracking County-Level Measles Cases in the US[20] 中文標題：美國郡級麻疹病例追蹤平台 類型：Research Letter（病例序列/監測資料） 導讀：介紹可追蹤美國「郡級」麻疹病例的公共資料平台與更新方式，對公衛監測、疫情溝通與資源配置有直接用途。 JAMA Network[21]
- Emergency Medicaid Spending for Undocumented Immigrants in the US[22] 中文標題：美國無證移民的 Emergency Medicaid 支出概況 類型：Research Letter（橫斷面/行政資料分析） 導讀：19 州 Medicaid claims 分析：Emergency Medicaid 佔總支出 2%（0.8%–4.1%），且 85% 支出用於美國出生/合法居留者；可校正政策討論的基線認知。 JAMA Network[23]
Viewpoint[edit | edit source]
- Advisory Committee on Immunization Practices Standards for Assessing Evidence[24] 中文標題：ACIP 評估疫苗證據的標準 類型：Viewpoint 導讀：聚焦 ACIP 如何（以及應如何）評讀與分級證據，幫助臨床/公衛讀者理解建議形成、透明度與不確定性溝通的關鍵。 JAMA Network[25]
- State Mifepristone Regulation Following GenBioPro v Raynes[26] 中文標題：GenBioPro v Raynes 後州層級米非司酮管制的變化 類型：Viewpoint（Women's Health；政策/法規） 導讀：梳理判決後各州對 mifepristone 的管制差異與趨勢，適合關注生殖健康服務可近性、醫療機構合規與臨床流程者。 JAMA Network[27]
- Evolving Hospital-at-Home to Meet the Needs of Children[28] 中文標題：兒科 Hospital-at-Home 的模式演進 類型：Viewpoint（醫療交付模式） 導讀：討論兒科居家住院如何從成人模式調整（安全、照護負擔、支付與公平），可作為建置/擴張兒科 HaH 專案的框架文章。 JAMA Network[29]
- The Make America Healthy Again Strategy Report[30] 中文標題：「Make America Healthy Again」策略報告的公共衛生觀點 類型：Viewpoint（健康政策） 導讀：從公共衛生與政策角度討論該策略報告的重點與可能影響，適合關注健康政策、風險溝通與健康不平等議題的讀者。 JAMA Network[31]
A Piece of My Mind[edit | edit source]
- The Last Night[32] 中文標題：最後一夜（醫療人文敘事） 類型：A Piece of My Mind（敘事散文） 導讀：以臨床照護情境書寫「最後一夜」的情感與專業界線；若想從人文視角補足純研究文章讀感，這篇值得快讀。 JAMA Network[33]
Editorial[edit | edit source]
- Artificial Intelligence and Diabetes Prevention[34] 中文標題：AI 與糖尿病預防：社論解讀 類型：Editorial（AI in Medicine） 導讀：搭配 AI vs 人類教練 DPP 試驗閱讀，社論聚焦 AI 介入的可近性、品質控管與監測重點，幫助判斷是否適合大規模部署。 JAMA Network[35]
- A Revision to Organ Failure Assessment in Critically Ill Patients[36] 中文標題：重症器官衰竭評估的修訂：社論 類型：Editorial（重症照護） 導讀：解讀 SOFA-2 的核心改動與臨床意涵（納入治療/器官支持、預測力提升），並提醒使用情境與未涵蓋器官系統等限制。 JAMA Network[37]
Review[edit | edit source]
- Cutaneous Melanoma: A Review[38] 中文標題：皮膚黑色素瘤：回顧 類型：Review（皮膚科/腫瘤；可做測驗） 導讀：皮膚型占約 95%；全球每年約 30 萬新案、9.6 萬死。早期以手術切除為主，進展期以免疫檢查點抑制與標靶治療；強調早期辨識與多專科照護。 JAMA Network[39]
JAMA Guide to Statistics and Methods[edit | edit source]
- Pattern-Mixture Models for Missing Data[40] 中文標題：缺失資料的 Pattern-Mixture Models 類型：Methods/Statistics（JAMA Guide to Statistics and Methods） 導讀：當缺失資料可能非隨機（MNAR）時，pattern-mixture models 以「缺失模式」分層建模並做敏感度分析，用來檢驗主要結論對缺失假設的穩健性。 JAMA Network[41]
JAMA Insights[edit | edit source]
- Recurrent Clostridioides difficile Infections[42] 中文標題：反覆性困難梭狀桿菌感染 類型：JAMA Insights（臨床要點） 導讀：以臨床實作角度整理復發 CDI 的診斷、治療選項與再發預防重點；若你在住院場景常遇到 CDI，這篇適合當作流程化複習。 JAMA Network[43]
Editor's Note[edit | edit source]
- AI in the Lab—Will It Really Change Drug Discovery?[44] 中文標題：實驗室中的 AI：真的會改變藥物發現嗎？ 類型：Editor's Note 導讀：從研究與產業視角檢視 AI 藥物發現的可行環節與瓶頸（仍需實驗驗證/外部驗證），適合想「校準期待值」的讀者短讀。 JAMA Network[45]
- “How Strangely Sweet”: Laryngitis and the Quiet Quirkiness of Senryu[46] 中文標題：《多麼奇異的甜美》：喉炎與 Senryu 的靜默怪奇 類型：Editor's Note（醫療人文） 導讀：以喉炎經驗為引，連結 senryu（短詩）與醫學觀察；屬人文短文，適合放鬆閱讀、換換腦袋。 JAMA Network[47]
Medical News[edit | edit source]
- New Insights on Circadian Health and Cardiometabolic Disease—Light, Sleep, Food, Exercise, and More[48] 中文標題：生理時鐘與心代謝健康：光、睡眠、飲食與運動的新洞見 類型：Medical News 導讀：報導 AHA 科學聲明：把「時間安排」納入處方（光照、睡眠、進食、運動的節律），作為心代謝風險管理的可操作介入方向。 JAMA Network[49]
- Gluten Sensitivity Is Common Around the World—Explanations Are Emerging[50] 中文標題：全球麩質敏感常見，機轉逐漸明朗 類型：Medical News（Quick Uptakes） 導讀：整理全球非乳糜瀉麩質敏感的盛行與特徵，並討論可能機轉；對消化科/家醫處理「疑似麩質不耐」諮詢有參考價值。 JAMA Network[51]
Medical News in Brief[edit | edit source]
- 2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants[52] 中文標題：2024–2025 COVID-19 疫苗對 JN.1 亞變異株仍具保護 類型：Medical News in Brief 導讀：簡訊整理新一季疫苗對 JN.1 亞變異株的保護訊息，可作為臨床門診與公衛溝通更新的快速素材。 JAMA Network[53]
- FDA Approves Nonhormonal Treatment for Menopausal Hot Flashes[54] 中文標題：FDA 核准新的非荷爾蒙停經熱潮紅治療 類型：Medical News in Brief 導讀：更新停經熱潮紅的非荷爾蒙治療選項，對不適合或不願使用荷爾蒙療法的族群，臨床可用來做選項式衛教。 JAMA Network[55]
- [Meta-Analysis: Viral Infections May Raise Cardiovascular Risks](Meta-Analysis: Viral Infections May Raise Cardiovascular Risks) 中文標題：荟萃分析：病毒感染後心血管風險可能上升 類型：Medical News in Brief 導讀：以綜合證據角度提醒病毒感染後可能伴隨心血管風險上升，適合用來提醒高風險病人追蹤與二級預防思維。 JAMA Network[56]
- Bacterial Vaginosis Treatment Should Involve All Partners, ACOG Says[57] 中文標題：ACOG：細菌性陰道炎治療應納入所有伴侶 類型：Medical News in Brief 導讀：反映對再感染控制的新立場（治療對象擴及所有伴侶）；臨床端可先讀這則簡訊，再回頭查實務指引細節。 JAMA Network[58]
- Updated Flu, RSV Vaccination Recommendations for Immunocompromised People[59] 中文標題：免疫功能低下者流感與 RSV 疫苗建議更新 類型：Medical News in Brief 導讀：快速更新免疫功能低下者的流感/RSV 接種建議，對門診接種排程、衛教與風險溝通有直接應用價值。 JAMA Network[60]
- [AAP: Leucovorin Not Recommended for Autism](AAP: Leucovorin Not Recommended for Autism) 中文標題：AAP：不建議以 Leucovorin 治療自閉症 類型：Medical News in Brief 導讀：提供門診面對補充/替代療法詢問時的依據與溝通起點；若常遇到家長提及 leucovorin，可先讀此則抓重點。 JAMA Network[61]
Poetry and Medicine[edit | edit source]
JAMA Revisited[edit | edit source]
- Sunshine and Health[64] 中文標題：日照與健康（JAMA Revisited） 類型：JAMA Revisited（歷史回顧） 導讀：重讀歷史內容，回顧「日照與健康」的早期醫學論述；適合教學、人文或醫史興趣讀者。 JAMA Network[65]
JAMA Patient Page[edit | edit source]
- Early-Onset Gastrointestinal Cancer[66] 中文標題：早發性腸胃道癌症（病人衛教頁） 類型：JAMA Patient Page（Patient Info） 導讀：以病人友善語言整理風險因子、警訊症狀與可能檢查/治療，適合門診衛教、共享決策或做成衛教單張。 JAMA Network[67]
Audio[edit | edit source]
- Lung Cancer Screening Benefits, Peripheral Neuropathy Review, Arsenic Exposure and Mortality, and more[68] 中文標題：本期音訊總覽：肺癌篩檢、周邊神經病變回顧、砷暴露與死亡等 類型：Audio 導讀：一集把多篇內容串成「可吸收的主線」，適合通勤快聽抓大方向，再回頭挑想深入的研究/評論文章。 JAMA Network[69]
- The Sequential Organ Failure Assessment (SOFA)-2 Score[70]-2%20Score) 中文標題：SOFA-2 評分：Podcast 導讀 類型：Audio（Podcast） 導讀：聚焦 SOFA-2 的新增構面與臨床使用情境，對 ICU 團隊評估是否導入新評分、如何解讀分數變化很有幫助。 JAMA Network[71]
- Diagnosis and Management of Cutaneous Melanoma[72] 中文標題：皮膚黑色素瘤的診斷與治療：Podcast 導讀 類型：Audio（Podcast） 導讀：用臨床觀點帶讀黑色素瘤從辨識、診斷到治療路徑，適合皮膚科/腫瘤科/家醫作為快速複習。 edhub.ama-assn.org[73]
- AI for Drug Discovery[74] 中文標題：AI 用於藥物發現：Podcast 導讀 類型：Audio（Podcast） 導讀：從 drug discovery 流程切入，討論 AI 可用場景與限制；若你關注轉譯研究或新藥研發，這集可快速對齊語境。 JAMA Network[75]
Comment & Response[edit | edit source]
- Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain[76] 中文標題：遠距/線上 CBT 慢性疼痛治療研究的讀者來函（之一） 類型：Comment & Response 導讀：就「遠距與線上 CBT 治療高衝擊慢性疼痛」研究提出解讀/方法學意見；若你讀過原研究，這封來函可快速看到爭點。 JAMA Network[77]
- Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain[78] 中文標題：遠距/線上 CBT 慢性疼痛治療研究的讀者來函（之二） 類型：Comment & Response 導讀：另一組作者針對同一主題提出補充觀點；適合想掌握不同讀者如何詮釋同一試驗結果的人快速掃讀。 JAMA Network[79]
- Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain—Reply[80] 中文標題：作者回覆：遠距/線上 CBT 慢性疼痛治療研究 類型：Comment & Response（Reply） 導讀：原作者回覆並澄清研究設計與結果詮釋，提供「如何讀懂這篇研究」的關鍵線索；建議與來函對照閱讀。 JAMA Network[81]
- Review on Uveitis[82] 中文標題：葡萄膜炎回顧文的讀者來函 類型：Comment & Response 導讀：針對 uveitis 回顧文章提出補充/質疑與臨床提醒；若你在眼科或內科常遇到 uveitis，這類來函可抓到爭議點。 JAMA Network[83]
- Review on Uveitis—Reply[84] 中文標題：作者回覆：葡萄膜炎回顧文 類型：Comment & Response（Reply） 導讀：作者回覆並補充其建議的理由與證據來源；適合在讀者來函後，用來釐清回顧文的臨床立場。 JAMA Network[85]
- Lower Urinary Tract Symptoms in Males[86] 中文標題：男性下泌尿道症狀（LUTS）議題讀者來函（之一） 類型：Comment & Response 導讀：針對男性 LUTS 的評估/治療觀點提出來函意見；可用來快速掃描臨床共識與分歧，之後再回讀原文更有效率。 JAMA Network[87]
- Lower Urinary Tract Symptoms in Males[88] 中文標題：男性下泌尿道症狀（LUTS）議題讀者來函（之二） 類型：Comment & Response 導讀：另一封針對 LUTS 的補充/不同角度來函；若你在泌尿科/家醫門診常處理 LUTS，建議與其他來函並讀抓重點。 JAMA Network[89]
- Lower Urinary Tract Symptoms in Males[90] 中文標題：男性下泌尿道症狀（LUTS）議題讀者來函（之三） 類型：Comment & Response 導讀：第三封針對 LUTS 的來函意見，提供不同作者的臨床詮釋；適合用來補齊指引解讀與實務落地的盲點。 JAMA Network[91]
- Lower Urinary Tract Symptoms in Males—Reply[92] 中文標題：作者回覆：男性 LUTS 議題 類型：Comment & Response（Reply） 導讀：作者整合多封來函的焦點並回覆，適合用來釐清 LUTS 評估與治療路徑的核心邏輯；建議作為總結段閱讀。 JAMA Network[93]
JAMA Masthead[edit | edit source]
- JAMA[94] 中文標題：JAMA 編輯與委員名錄（Masthead） 類型：JAMA Masthead 導讀：列出期刊編輯、編委與工作人員名錄；臨床讀者可略過，但投稿、引用或查詢期刊運作資訊時很實用。 JAMA Network[95]
References[edit | edit source]
- ↑ "JAMA New Issue Summary". ChatGPT. Retrieved 2025-12-18.
- ↑ "Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score". Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial". An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Arsenic Exposure Reduction and Chronic Disease Mortality". Arsenic Exposure Reduction and Chronic Disease Mortality. Retrieved 2025-12-18.
- ↑ "PubMed". pubmed.ncbi.nlm.nih.gov. Retrieved 2025-12-18.
- ↑ "Cutaneous Melanoma: A Review". Cutaneous Melanoma: A Review. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Recurrent Clostridioides difficile Infections". Recurrent Clostridioides difficile Infections. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Audio Highlights: November 21, 2025". Audio Highlights: November 21, 2025. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial". An AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program: A Randomized Clinical Trial. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score". Development and Validation of the Sequential Organ Failure Assessment (SOFA)-2 Score. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Arsenic Exposure Reduction and Chronic Disease Mortality". Arsenic Exposure Reduction and Chronic Disease Mortality. Retrieved 2025-12-18.
- ↑ "PubMed". pubmed.ncbi.nlm.nih.gov. Retrieved 2025-12-18.
- ↑ "Tracking County-Level Measles Cases in the US". Tracking County-Level Measles Cases in the US. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Emergency Medicaid Spending for Undocumented Immigrants in the US". Emergency Medicaid Spending for Undocumented Immigrants in the US. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Advisory Committee on Immunization Practices Standards for Assessing Evidence". Advisory Committee on Immunization Practices Standards for Assessing Evidence. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "State Mifepristone Regulation Following GenBioPro v Raynes". State Mifepristone Regulation Following GenBioPro v Raynes. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Evolving Hospital-at-Home to Meet the Needs of Children". Evolving Hospital-at-Home to Meet the Needs of Children. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "The Make America Healthy Again Strategy Report". The Make America Healthy Again Strategy Report. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "The Last Night". The Last Night. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Artificial Intelligence and Diabetes Prevention". Artificial Intelligence and Diabetes Prevention. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "A Revision to Organ Failure Assessment in Critically Ill Patients". A Revision to Organ Failure Assessment in Critically Ill Patients. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Cutaneous Melanoma: A Review". Cutaneous Melanoma: A Review. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Pattern-Mixture Models for Missing Data". Pattern-Mixture Models for Missing Data. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Recurrent Clostridioides difficile Infections". Recurrent Clostridioides difficile Infections. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "AI in the Lab—Will It Really Change Drug Discovery?". AI in the Lab—Will It Really Change Drug Discovery?. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ ""How Strangely Sweet": Laryngitis and the Quiet Quirkiness of Senryu". “How Strangely Sweet”: Laryngitis and the Quiet Quirkiness of Senryu. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "New Insights on Circadian Health and Cardiometabolic Disease—Light, Sleep, Food, Exercise, and More". New Insights on Circadian Health and Cardiometabolic Disease—Light, Sleep, Food, Exercise, and More. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Gluten Sensitivity Is Common Around the World—Explanations Are Emerging". Gluten Sensitivity Is Common Around the World—Explanations Are Emerging. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants". 2024-2025 COVID-19 Vaccines Protected Against JN.1 Subvariants. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "FDA Approves Nonhormonal Treatment for Menopausal Hot Flashes". FDA Approves Nonhormonal Treatment for Menopausal Hot Flashes. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Bacterial Vaginosis Treatment Should Involve All Partners, ACOG Says". Bacterial Vaginosis Treatment Should Involve All Partners, ACOG Says. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Updated Flu, RSV Vaccination Recommendations for Immunocompromised People". Updated Flu, RSV Vaccination Recommendations for Immunocompromised People. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Hush". chatgpt.com. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Sunshine and Health". Sunshine and Health. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Early-Onset Gastrointestinal Cancer". Early-Onset Gastrointestinal Cancer. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Lung Cancer Screening Benefits, Peripheral Neuropathy Review, Arsenic Exposure and Mortality, and more". Lung Cancer Screening Benefits, Peripheral Neuropathy Review, Arsenic Exposure and Mortality, and more. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "The Sequential Organ Failure Assessment (SOFA)-2 Score". The Sequential Organ Failure Assessment (SOFA)-2 Score. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Diagnosis and Management of Cutaneous Melanoma". Diagnosis and Management of Cutaneous Melanoma. Retrieved 2025-12-18.
- ↑ "edhub.ama-assn.org". edhub.ama-assn.org. Retrieved 2025-12-18.
- ↑ "AI for Drug Discovery". AI for Drug Discovery. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain". Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain". Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain—Reply". Telehealth and Online Cognitive Behavioral Therapy–Based Treatments for High-Impact Chronic Pain—Reply. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Review on Uveitis". Review on Uveitis. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Review on Uveitis—Reply". Review on Uveitis—Reply. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Lower Urinary Tract Symptoms in Males". Lower Urinary Tract Symptoms in Males. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Lower Urinary Tract Symptoms in Males". Lower Urinary Tract Symptoms in Males. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Lower Urinary Tract Symptoms in Males". Lower Urinary Tract Symptoms in Males. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "Lower Urinary Tract Symptoms in Males—Reply". Lower Urinary Tract Symptoms in Males—Reply. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.
- ↑ "JAMA". chatgpt.com. Retrieved 2025-12-18.
- ↑ "JAMA Network". JAMA Network. Retrieved 2025-12-18.